United Therapeutics Co. (NASDAQ:UTHR)’s share price was up 6.5% during trading on Tuesday . The stock traded as high as $92.00 and last traded at $91.79, approximately 726,146 shares were traded during trading. An increase of 85% from the average daily volume of 392,936 shares. The stock had previously closed at $86.20.
Several equities analysts have recently commented on UTHR shares. HC Wainwright restated a “hold” rating and set a $85.00 price target on shares of United Therapeutics in a research report on Friday, November 1st. Wedbush restated a “buy” rating and set a $237.00 price target on shares of United Therapeutics in a research report on Sunday, December 15th. Credit Suisse Group restated a “buy” rating and set a $113.00 price target on shares of United Therapeutics in a research report on Tuesday, December 10th. ValuEngine lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 3rd. Finally, Zacks Investment Research lowered shares of United Therapeutics from a “hold” rating to a “sell” rating and set a $93.00 price target for the company. in a research report on Thursday, January 2nd. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $115.09.
The stock’s 50-day moving average is $89.75 and its 200-day moving average is $84.37. The stock has a market cap of $3.76 billion, a P/E ratio of 6.86, a price-to-earnings-growth ratio of -1.40 and a beta of 0.95. The company has a current ratio of 4.11, a quick ratio of 3.91 and a debt-to-equity ratio of 0.28.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.34 by $0.82. The firm had revenue of $401.50 million during the quarter, compared to analyst estimates of $342.28 million. United Therapeutics had a negative net margin of 6.04% and a negative return on equity of 3.54%. United Therapeutics’s revenue was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.98 EPS. On average, equities analysts forecast that United Therapeutics Co. will post -0.96 EPS for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Alpha Windward LLC grew its position in United Therapeutics by 4,012.7% in the 4th quarter. Alpha Windward LLC now owns 5,511 shares of the biotechnology company’s stock valued at $485,000 after buying an additional 5,377 shares in the last quarter. DNB Asset Management AS acquired a new stake in United Therapeutics in the 4th quarter valued at about $10,458,000. Maverick Capital Ltd. acquired a new stake in United Therapeutics in the 3rd quarter valued at about $1,018,000. Squarepoint Ops LLC lifted its holdings in United Therapeutics by 373.3% in the 3rd quarter. Squarepoint Ops LLC now owns 118,810 shares of the biotechnology company’s stock valued at $9,475,000 after acquiring an additional 93,707 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in United Therapeutics by 41.5% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,532 shares of the biotechnology company’s stock valued at $2,196,000 after acquiring an additional 8,071 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.
United Therapeutics Company Profile (NASDAQ:UTHR)
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.